Core Insights - iRhythm Holdings, Inc. presented new clinical evidence at the ACC 2026 Annual Scientific Sessions, reinforcing the effectiveness of its Zio ambulatory ECG monitoring service in identifying clinically relevant arrhythmias across diverse patient populations [1][6][14] Clinical Evidence - Two retrospective analyses highlighted the high prevalence of clinically actionable arrhythmias among patients with chronic kidney disease (CKD) and diabetes, indicating that these conditions significantly increase arrhythmia risk [3][4][7] - A study involving 657,147 individuals showed that 48% of patients with CKD and 47% of those with both diabetes and CKD experienced clinically actionable arrhythmias, compared to 39% of patients with diabetes alone and 35% without either condition [7] - Another analysis of 162,531 individuals found that higher body weight correlated with increased detection of atrial fibrillation (AF), with prevalence rising from 4.5% in normal/underweight patients to 6.5% in those with severe obesity [5][7] AI and Education Initiatives - iRhythm emphasized its leadership in AI within cardiology, with Chief Medical Officer Mintu Turakhia delivering a keynote on integrating AI into clinical practice [2][10] - The launch of iRhythm Academy aims to enhance clinician education on ambulatory cardiac monitoring, providing interactive courses and resources to improve patient care [2][13] Market Opportunity - With an estimated 27 million people in the U.S. at risk for undiagnosed arrhythmias annually, iRhythm is focused on proactive cardiac monitoring and has partnered with Lucem Health to utilize predictive AI for identifying high-risk patients [9][10] - Data from previous studies indicated that arrhythmias often precede major health issues, highlighting the potential for earlier detection and intervention through iRhythm's monitoring solutions [8][9]

Core Insights - iRhythm Technologies published a study in Heart Rhythm, analyzing data from over 1.1 million patients using its Zio long-term continuous monitoring (LTCM) service, highlighting the importance of long-term monitoring for arrhythmia detection [1][3][4] Group 1: Study Findings - The study revealed that short-term monitoring (24-48 hours) often fails to detect actionable arrhythmias, even in patients reporting daily symptoms, with 64% of daily-symptom patients having undetected arrhythmias within the first 48 hours [3][4] - Less than 20% of patients documented symptoms coinciding with arrhythmic episodes, indicating a low symptom-rhythm correlation [4] - The mean time to first detected arrhythmia exceeded 48 hours for all arrhythmia types, regardless of symptom frequency, emphasizing the clinical value of Zio LTCM for up to 14 days [4][5] Group 2: Real-World Evidence and Compliance - Data presented at the AHA Scientific Sessions 2025 confirmed high compliance and data quality for at-home self-application of Zio LTCM devices, with median wear time exceeding 13.8 days and analyzable ECG time over 98% [6][8] - The MyZio mobile app usage was significantly higher among home-enrolled patients (52% vs. 17%), leading to better compliance and fewer early terminations [8] Group 3: CKM Syndrome Insights - New analyses presented at AHA 2025 revealed that arrhythmias can emerge earlier across the cardio-kidney-metabolic (CKM) syndrome continuum, with 58% of CKD patients experiencing arrhythmias before CKD diagnosis [10][11] - The incidence of arrhythmias increased with CKM stages, highlighting the need for early rhythm assessment in at-risk populations [10][11] Group 4: Company Commitment and Innovations - iRhythm aims to reach the estimated 27 million people in the U.S. at risk for undiagnosed arrhythmias through scalable, clinically validated solutions [13] - The collaboration with Lucem Health focuses on combining ECG monitoring with AI-powered risk stratification to enhance early detection of arrhythmia risk [14] - iRhythm's comprehensive clinical evidence program includes over 125 original research manuscripts and insights from more than 2 billion hours of curated heartbeat data, reinforcing its commitment to improving patient outcomes [15]